Vanguard Portfolio Management
HRTX icon

Vanguard Portfolio Management’s Heron Therapeutics HRTX Stock Holding History

Vanguard Portfolio Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$675K Buy
1,580,510
+271,198
+21% +$217K ﹤0.01% 3035
2026
Q1 		$1.05M Buy
+1,309,312
New +$1.52M ﹤0.01% 2784

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Vanguard Portfolio Management's HRTX Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Heron Therapeutics (HRTX) stake by 21% in Q2 2026, buying an estimated $217K and bringing the position to 1,580,510 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #3035.

Vanguard Portfolio Management first reported a position in HRTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.05M in Q1 2026. 161 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Vanguard Portfolio Management held 1,580,510 shares of Heron Therapeutics worth $675K as of Q2 2026.
  • Vanguard Portfolio Management bought 271,198 Heron Therapeutics shares in Q2 2026, an estimated $217K.
  • Heron Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #3035 holding.
  • Vanguard Portfolio Management first reported a position in Heron Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Heron Therapeutics position peaked at $1.05M in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.